Value
6.9/10data confidence 33%| Component | Sub-score |
|---|---|
| P/S | 3.8 |
| Analyst target | 9.0 |
VSTM · Why this verdict
Why Verastem (VSTM) is rated SELL
Updated
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
VerdictSELL
Overall score5.7/10
ConfidenceMEDIUM
MacroRISK_OFF
TrendMatrix Research · core thesis
Engine thesis — one sentence
Verastem pairs a four-quarter earnings beat streak and rapid revenue ramp with heavy cash burn, single-product concentration and meaningful short interest in a binary biotech setup.
Falsifiable statement — pillar-level invalidators below. Engine-derived; not personalized advice.
Thesis pillars
| Pillar | Expectation | Trend |
|---|---|---|
Verastem has beaten EPS estimates in 4 of 4 recent quarters, with an average surprise of 17.7%. Bull case | The streak extends at the next report, with EPS beating the estimate again. | →Stable |
| CounterEarlier history shows five misses in the preceding eight quarters, so the streak could be recent luck. | ||
Quarterly revenue rose to $40.1M from $2.1M a year earlier, a sharp commercial ramp. Earnings | Quarterly revenue holds above $30M, in line with the next-quarter estimate of $29.1M. | →Stable |
| CounterThe latest quarter may include one-time or milestone revenue, as the next-quarter estimate is well below $40.1M. | ||
The company is cash-burning, with free cash flow at -118% of revenue. Quality breakdown | Free cash flow margin improves above -50% of revenue as sales scale. | →Stable |
| CounterRule-of-40 and gross margin scores are strong, suggesting burn is shrinking as revenue grows. | ||
Revenue depends on a single product combination, flagged as a concentration risk. Bear case | A second product or indication starts contributing meaningful revenue. | →Stable |
| CounterConcentrated launches are common for a young commercial biotech and can still produce rapid growth. | ||
The analyst-based target of $13.05 sits 55.7% above the $8.38 price, with light coverage of 9 analysts. Estimated upside | The analyst target holds above $12 as the price closes the gap. | →Stable |
| CounterShort interest of 20% and implied volatility of 425% show the market doubts the target. | ||
Verastem has beaten EPS estimates in 4 of 4 recent quarters, with an average surprise of 17.7%.
→StableBull case
- Expectation
- The streak extends at the next report, with EPS beating the estimate again.
CounterEarlier history shows five misses in the preceding eight quarters, so the streak could be recent luck.
Quarterly revenue rose to $40.1M from $2.1M a year earlier, a sharp commercial ramp.
→StableEarnings
- Expectation
- Quarterly revenue holds above $30M, in line with the next-quarter estimate of $29.1M.
CounterThe latest quarter may include one-time or milestone revenue, as the next-quarter estimate is well below $40.1M.
The company is cash-burning, with free cash flow at -118% of revenue.
→StableQuality breakdown
- Expectation
- Free cash flow margin improves above -50% of revenue as sales scale.
CounterRule-of-40 and gross margin scores are strong, suggesting burn is shrinking as revenue grows.
Revenue depends on a single product combination, flagged as a concentration risk.
→StableBear case
- Expectation
- A second product or indication starts contributing meaningful revenue.
CounterConcentrated launches are common for a young commercial biotech and can still produce rapid growth.
The analyst-based target of $13.05 sits 55.7% above the $8.38 price, with light coverage of 9 analysts.
→StableEstimated upside
- Expectation
- The analyst target holds above $12 as the price closes the gap.
CounterShort interest of 20% and implied volatility of 425% show the market doubts the target.
Per-dimension breakdown
Quality
4.7/10data confidence 100%| Component | Sub-score |
|---|---|
| ROA | 0.0 |
| Gross margin | 10.0 |
| Op margin | 0.0 |
| Current ratio | 7.8 |
| FCF quality | 0.0 |
| Moat | 5.8 |
| Rule of 40 | 9.5 |
| Piotroski F | 4.4 |
- ▸Cash-burning: FCF -118% of revenue
- ▸Rule of 40: 1657 (elite)
Growth
5.0/10data confidence 50%Momentum
7.1/10data confidence 100%| Component | Sub-score |
|---|---|
| RSI | 5.5 |
| MACD | 7.3 |
| OBV | 10.0 |
| MA position | 8.0 |
| Volume | 4.7 |
- ▸Volume accumulation (rising OBV)
- ▸Above 200-MA but MA slope flat
Sentiment
8.2/10data confidence 100%| Component | Sub-score |
|---|---|
| LLM sentiment | 6.6 |
| Analyst rating | 8.0 |
| Price target | 10.0 |
- ▸LLM news sentiment: +0.33 (n=10)
- ▸Light analyst coverage (9.0) — signal dampened
- ▸Analyst upside: 99%
Insider
5.9/10data confidence 100%| Component | Sub-score |
|---|---|
| materiality | 4.5 |
| insider conviction | 2.0 |
| holder change | 10.0 |
| notable moves | 7.0 |
- ▸Modest insider selling — $381,484 (0.046% of mkt cap)
- ▸Institutions accumulating
Peer rank
3.9/10data confidence 80%| Component | Sub-score |
|---|---|
| value rank | 4.9 |
| quality rank | 0.0 |
| growth rank | 10.0 |
- ▸Industry growth leader
Technical
3.6/10data confidence 100%| Component | Sub-score |
|---|---|
| bollinger | 1.3 |
| support resistance | 3.6 |
| 52w position | 6.0 |
Risk (lower is worse)
3.3/10data confidence 100%| Component | Sub-score |
|---|---|
| short interest | 1.8 |
| days to cover | 4.2 |
| volatility | 0.0 |
| put call | 0.0 |
| beta | 10.0 |
| debt equity | 3.6 |
- ▸High short interest justified: 17%
- ▸Elevated put/call: 2.69
- ▸Concentration risks: 1 HIGH, 1 MED (10-K Item 1A — sized via position_sizing, validated via buy_confidence)
Catalyst
7.5/10data confidence 100%| Component | Sub-score |
|---|---|
| erm | 5.0 |
| earnings history | 10.0 |
| earnings timing | 5.0 |
| surprise avg | 9.6 |
| news activity | 8.0 |
- ▸Perfect beat streak: 4Q
How the verdict was assembled
Engine trigger
Multiple concerning factors. Consider reducing position.
Engine technical detail
verdict_path:
L4:PATH_F_SELLPassed (8)
- MOMENTUM:7.1>=5.5
- ASYMMETRY:4.9>=1.5
- INSIDER:OK
- 8K:CLEAN
- NEWS_BOOST:ANALYST:0.70
- EARNINGS_PROXIMITY:18d clear
- SEMI_CYCLE_PEAK:CLEAR
- MATERIALS_CYCLE_PEAK:CLEAR
Failed (0)
none
Warning (0)
none
Reward-to-Risk
4.88
Upside
+73.2%
Downside
15.0%
Sizing output
AVOID
SetupBreakout — Golden cross, above all MAs, RSI 58, MACD bullish
EdgeCatalyst-Driven — Earnings in 18d with 4/4 beat streak
SuitabilitySpeculative — Binary industry: Biotechnology
Investment implication
The F-path SELL output reflects an overall score of 4.7 below the 5.6 soft trigger — multiple weakening dimensions accumulated rather than a single hard-floor breach. The strongest dimension ( Sentiment at 8.2) was not enough to lift the adjusted overall above the threshold. Current asymmetry R:R is 4.88 — supplementary context, not the trigger for this path.
The strongest dimensions are Sentiment at 8.2, Catalyst at 7.5, and Momentum at 7.1; the weakest are Risk (lower is worse) at 3.3, Technical at 3.6, and Peer rank at 3.9. The V9 engine cleared all gates, producing an asymmetric reward-to-risk of 4.88 and an engine sizing output of AVOID.
What would invalidate the thesis
Falsifying conditions — when triggered, the corresponding pillar's thesis is invalidated.
- P1Earnings Beat Streak
Trip ifEPS surprise falls below 0% at the report on 2026-11-03.
- P2Rapid Revenue Ramp
Trip ifQuarterly revenue falls below $30M from current $40.1M.
- P3Heavy Cash Burn
Trip ifFree cash flow margin rises above -50% of revenue from current -118%.
- P4Single Product Concentration
Trip ifSingle-product share of revenue falls below 70%.
- P5Analyst Target Upside
Trip ifAnalyst target falls below $10 from current $13.05.